Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Alexander Drilon, Zishuo I. Hu, Gillianne G.Y. Lai, Daniel S.W. Tan

Research output: Contribution to journalComment/debate

27 Scopus citations

Abstract

Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.175 (2017) In the online and PDF versions of this Review, in the ‘Acquired resistance’ subsection, RETI788N was erroneously written as RETI887N, and the ROS1G2032R mutation was written as ROS1D2033N. This information has now been corrected in the online and PDF versions of the Review.

Original languageEnglish
Pages (from-to)150
Number of pages1
JournalNature Reviews Clinical Oncology
Volume15
Issue number3
DOIs
StatePublished - Mar 2018

Fingerprint

Dive into the research topics of 'Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes'. Together they form a unique fingerprint.

Cite this